GSK (GLAXF)
GSK (GLAXF) Stock Price, Analysis & Data
| Geld | 24.29 |
| Marktkapitalisierung | 101.82 Mrd |
| Umsatz (TTM) | 33.2 Mrd |
| Nettogewinn (TTM) | 4.82 Mrd |
| Beta | 0.29 |
| EPS (ttm) | 1.61 |
| KGV (TTM) | 15.99 |
| Forward-KGV | 11.55 |
| KBV (TTM) | 4.29 |
| KUV (TTM) | 3.07 |
| Earnings Date | Oct 28, 2026 |
| Brief | 26.79 |
| Volumen | 150 |
| Ø Vol. (20D) | 729 |
| Eröffnung | 24.29 |
| Vortagesschluss | 25.19 |
| Tagesspanne | 24.29 - 24.29 |
| 52-Wk Range | 18.99 - 31.48 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | $0.9 (3.59%) |
| Ex-Dividenden-Datum | 13. Aug. 2026 |
Über GLAXF
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respirator...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von GSK 32.67 Mrd, ein Anstieg von 4.11% im Vergleich zum Vorjahr (31.38 Mrd). Der Gewinn lag bei 5.72 Mrd, ein Anstieg von 121.98 %.
FinanzberichteAnalysten erwarten einen Umsatz von ... Upgrade
vor 11 Stunden · Insider Monkey
Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover rea...
